

- **Name:** Seock-Ah Im
  - **Current Position & Affiliation:** Department of Internal Medicine  
Seoul National University Hospital
  - **Country:** Republic of Korea
- 

**• Educational Background:**

- 1999 Ph.D. Ewha Womans University, College of Medicine, Seoul, Korea
- 1995 M.S. Ewha Womans University, College of Medicine, Seoul, Korea
- 1991 M.D. Ewha Womans University, College of Medicine, Seoul, Korea

**• Professional Experience:**

- 2019.7 ~ present Director, Cancer Research Institute, Seoul National University
- 2003.9 ~ present Professor, Associate Professor, Assistant Professor  
Department of Internal Medicine, Seoul National University, College of Medicine
- 2008.3 ~ 2009.2 Translational Research Scientist, AstraZeneca Oncology R&D center,  
Cheshire, UK
- 2007.3 ~ 2010.2 Korean Cancer Study Group AstraZeneca Oncology Fellowship
- 2000.1 ~ 2003.8 Instructor, Assistant Professor, Department of Internal Medicine, Ewha  
Womans University, College of Medicine
- 1997.3 ~ 1998.9 Research Fellow at Division of Internal Medicine, Department of Neuro-  
Oncology, M.D. Anderson Cancer Center, Houston, Texas, USA
- 1996.3 ~ 1997.2 Clinical Fellowship, Division of Hemato-oncology, Department of Internal  
Medicine, Seoul National University Hospital

**• Professional Organizations:**

- 2018.6 ~ present Director of Scientific Committee, Korean Society of Medical  
Oncology(KSMO)
- 2019.6 ~ present Board of Directors, Korea Cancer Research Foundation (KCRF)
- 2020.6 ~ 2022.6 Director of International Affairs Committee, Korean Cancer Association (KCA)
- 2021.3 ~ present Board of Directors, Translation Research in Oncology (TRIO)
- 2021.3 ~ present Clinical Practice Guidelines(CPG) committee, European Society for Medical  
Oncology (ESMO)
- 2021.3 ~ present Chairperson of External Cooperation Committee, Korean Cancer Study Group  
(KCSG)
- 2002.5 ~ present Member, American Society of Clinical Oncology (ASCO)

**• Main Scientific Publications:**

1. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 Jul 25;381(4):307-316.
2. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019 Dec;20(12):1750-1759.

3. Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. *Nat Biomed Eng.* 2018 Apr;2(4):239-253.
4. Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts. *Nat Commun.* 2021 Aug 10;12(1):4840.
5. Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. *Clin Cancer Res.* 2022 Mar 1;28(5):851-8592.